NaNotics 2020 Overview

In this 15 minute video, NaNotics CEO Lou Hawthorne explains the technology – including the advantages of NaNots versus antibody drugs – and outlines 6 target priorities as well as preclinical efficacy stemming from depletion of some of these targets in mouse models of disease. NaNotics CTO, John Dodgson, PhD, describes the company’s portfolio of granted and pending patents. A summary of past and planned financing is included for prospective investors. The video ends with the company’s new 4-minute bio-animation.